ProQR Therapeutics (PRQR) News Today → Executive Order To Wipe Out Your Bank Accounts (From Oasis Gold) (Ad) Free PRQR Stock Alerts $1.88 +0.03 (+1.62%) (As of 09:45 AM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 6, 2024 | americanbankingnews.comProQR Therapeutics (NASDAQ:PRQR) Stock Rating Lowered by StockNews.comJune 5, 2024 | marketbeat.comProQR Therapeutics (NASDAQ:PRQR) Rating Lowered to Sell at StockNews.comStockNews.com downgraded shares of ProQR Therapeutics from a "hold" rating to a "sell" rating in a report on Wednesday.June 5, 2024 | marketbeat.comProQR Therapeutics (NASDAQ:PRQR) Shares Pass Above 50 Day Moving Average of $2.02ProQR Therapeutics (NASDAQ:PRQR) Stock Crosses Above 50-Day Moving Average of $2.02May 13, 2024 | finance.yahoo.comShareholders in ProQR Therapeutics (NASDAQ:PRQR) are in the red if they invested five years agoMay 11, 2024 | marketbeat.comProQR Therapeutics (NASDAQ:PRQR) Cut to "Sell" at StockNews.comStockNews.com downgraded shares of ProQR Therapeutics from a "hold" rating to a "sell" rating in a report on Friday.May 10, 2024 | markets.businessinsider.comProQR’s Axiomer Platform Technology Shows Promise: Analyst Maintains Buy Rating on Robust Editing Efficacy and Clinical Development PotentialMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for ProQR on Promising RNA Editing Technology and Solid Financial FootingMay 10, 2024 | marketbeat.comProQR Therapeutics' (PRQR) "Buy" Rating Reaffirmed at Chardan CapitalChardan Capital reiterated a "buy" rating and issued a $2.50 target price on shares of ProQR Therapeutics in a report on Friday.May 9, 2024 | finanznachrichten.deProQR Therapeutics N.V.: ProQR Announces First Quarter 2024 Operating and Financial ResultsMay 9, 2024 | globenewswire.comProQR Announces First Quarter 2024 Operating and Financial ResultsMay 8, 2024 | markets.businessinsider.comBuy Recommendation on ProQR’s Innovative RNA Editing Platform and Promising Clinical ProspectsMay 8, 2024 | stockhouse.comProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer(TM) RNA Editing Program Targeting NTCP for Cholestatic DiseasesMay 8, 2024 | finance.yahoo.comProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer™ RNA Editing Program Targeting NTCP for Cholestatic DiseasesApril 24, 2024 | stockhouse.comProQR Highlights Upcoming Presentations on Axiomer(TM) RNA Editing at ASGCT 27th Annual MeetingApril 23, 2024 | globenewswire.comProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024April 22, 2024 | finance.yahoo.comProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual MeetingApril 22, 2024 | globenewswire.comProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual MeetingApril 21, 2024 | uk.investing.comProQR retains key patent for RNA editing technologyApril 20, 2024 | stockhouse.comProQR Achieves Successful Defense of New Challenge to its Axiomer(TM) IP PortfolioApril 19, 2024 | globenewswire.comProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP PortfolioApril 18, 2024 | marketbeat.comCitigroup Raises ProQR Therapeutics (NASDAQ:PRQR) Price Target to $2.00Citigroup increased their target price on shares of ProQR Therapeutics from $1.80 to $2.00 and gave the company a "buy" rating in a research report on Thursday.April 8, 2024 | finance.yahoo.comProQR Therapeutics N.V. (PRQR)March 29, 2024 | marketbeat.comProQR Therapeutics (NASDAQ:PRQR) Given Consensus Recommendation of "Buy" by AnalystsProQR Therapeutics (NASDAQ:PRQR - Get Free Report) has been assigned a consensus rating of "Buy" from the five analysts that are covering the firm, Marketbeat.com reports. Five analysts have rated the stock with a buy recommendation. The average 1-year price target among brokers that have coveredMarch 18, 2024 | marketbeat.comProQR Therapeutics (NASDAQ:PRQR) Given "Buy" Rating at HC WainwrightHC Wainwright restated a "buy" rating and issued a $5.00 price objective on shares of ProQR Therapeutics in a report on Thursday.March 18, 2024 | marketbeat.comChardan Capital Boosts ProQR Therapeutics (NASDAQ:PRQR) Price Target to $2.50Chardan Capital lifted their price objective on shares of ProQR Therapeutics from $2.00 to $2.50 and gave the company a "buy" rating in a research note on Thursday.March 15, 2024 | marketbeat.comProQR Therapeutics (NASDAQ:PRQR) Short Interest UpdateProQR Therapeutics (NASDAQ:PRQR - Get Free Report) saw a large drop in short interest in February. As of February 29th, there was short interest totalling 263,900 shares, a drop of 17.3% from the February 14th total of 319,000 shares. Based on an average trading volume of 302,700 shares, the days-to-cover ratio is currently 0.9 days. Approximately 0.6% of the shares of the stock are short sold.March 14, 2024 | markets.businessinsider.comBuy Rating Affirmed: ProQR’s Axiomer Platform Shows Promising Potential in CNS and Metabolic DisordersMarch 14, 2024 | markets.businessinsider.comBuy Rating Affirmed for ProQR on Strong Financials and Promising RNA Editing PlatformMarch 14, 2024 | finance.yahoo.comProQR Therapeutics Full Year 2023 Earnings: Misses ExpectationsMarch 13, 2024 | globenewswire.comProQR Announces Year End 2023 Operating and Financial ResultsMarch 11, 2024 | marketbeat.comProQR Therapeutics (NASDAQ:PRQR) Upgraded by StockNews.com to BuyStockNews.com upgraded ProQR Therapeutics from a "hold" rating to a "buy" rating in a research report on Monday.February 18, 2024 | finance.yahoo.comPRQR Mar 2024 2.500 callFebruary 16, 2024 | wsj.comProQR Therapeutics N.V.February 15, 2024 | finance.yahoo.comProQR Announces Japanese Axiomer™ Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA EditingFebruary 8, 2024 | marketbeat.comProQR Therapeutics (NASDAQ:PRQR) Given Consensus Recommendation of "Buy" by BrokeragesProQR Therapeutics (NASDAQ:PRQR - Get Free Report) has been assigned an average recommendation of "Buy" from the five research firms that are presently covering the firm, Marketbeat reports. Five analysts have rated the stock with a buy recommendation. The average 12 month price target among analyFebruary 2, 2024 | marketbeat.comStockNews.com Downgrades ProQR Therapeutics (NASDAQ:PRQR) to HoldStockNews.com lowered shares of ProQR Therapeutics from a "buy" rating to a "hold" rating in a report on Friday.January 30, 2024 | stocknews.com4 Biotech Stocks With Massive Buy PotentialJanuary 25, 2024 | marketbeat.comStockNews.com Upgrades ProQR Therapeutics (NASDAQ:PRQR) to BuyStockNews.com raised ProQR Therapeutics from a "hold" rating to a "buy" rating in a research report on Thursday.January 19, 2024 | finanznachrichten.deProQR Therapeutics N.V.: ProQR Highlights New Platform Data from Presentation on Axiomer RNA Editing Technology at Deaminet 2024January 19, 2024 | finance.yahoo.comProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024January 15, 2024 | finance.yahoo.comWhile institutions invested in ProQR Therapeutics N.V. (NASDAQ:PRQR) benefited from last week's 12% gain, individual investors stood to gain the mostJanuary 13, 2024 | marketbeat.comProQR Therapeutics (NASDAQ:PRQR) Sees Large Decrease in Short InterestProQR Therapeutics (NASDAQ:PRQR - Get Free Report) was the target of a significant decrease in short interest during the month of December. As of December 31st, there was short interest totalling 680,400 shares, a decrease of 30.6% from the December 15th total of 981,100 shares. Based on an average trading volume of 204,200 shares, the short-interest ratio is currently 3.3 days. Currently, 1.4% of the company's shares are sold short.January 6, 2024 | markets.businessinsider.comBuy Rating Affirmed for ProQR on Strategic Partnership and Promising Axiomer RNA Editing PlatformJanuary 5, 2024 | finanznachrichten.deProQR Therapeutics N.V.: ProQR and Rett Syndrome Research Trust Join Forces with Axiomer RNA Editing CollaborationJanuary 5, 2024 | benzinga.comProQR Therapeutics Stock (NASDAQ:PRQR) Dividends: History, Yield and DatesJanuary 5, 2024 | finance.yahoo.comProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing CollaborationJanuary 4, 2024 | marketbeat.comProQR Therapeutics (NASDAQ:PRQR) Stock Rating Upgraded by StockNews.comStockNews.com raised ProQR Therapeutics from a "hold" rating to a "buy" rating in a research report on Thursday.December 28, 2023 | finance.yahoo.comIs ProQR (PRQR) Stock a Solid Choice Right Now?December 9, 2023 | markets.businessinsider.comProQR’s Strategic Divestiture and Strong Financial Outlook Justify Buy RatingDecember 8, 2023 | finance.yahoo.comProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets Get ProQR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRQR and its competitors with MarketBeat's FREE daily newsletter. Email Address Executive Order To Wipe Out Your Bank Accounts (Ad)Don't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of opportunity to protect your interests is closing fast. Click Here To Get Your FREE Guide Now! PRQR Media Mentions By Week PRQR Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PRQR News Sentiment▼-0.080.76▲Average Medical News Sentiment PRQR News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PRQR Articles This Week▼31▲PRQR Articles Average Week Get ProQR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRQR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Dianthus Therapeutics News Today Arbutus Biopharma News Today Mineralys Therapeutics News Today Silence Therapeutics News Today Pharming Group News Today ORIC Pharmaceuticals News Today Pharvaris News Today Zymeworks News Today Savara News Today Travere Therapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PRQR) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersAlert: Your Bank is Dying – Act Now or Lose Everything!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put...Priority Gold | SponsoredTrump convicted... now what?Unexpected Twist to Trump's Trial Most folks sense there's more to the Trump trial than meets the eye. B...Stansberry Research | SponsoredIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...Smallcaps Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | Sponsored